Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics

The Pharmacogenomics Journal volume 2, pages 400–407 (2002)Cite this article

Abstract

The CYP2D6 gene codes for human cytochrome P450 2D6 enzyme, which is responsible for the metabolism of many psychiatric drugs. In schizophrenic patients treated with neuroleptics, decreased or loss of function CYP2D6 alleles may contribute to the development of tardive dyskinesia (TD), a movement disorder that frequently occurs with chronic neuroleptic treatment. The goal of this study was to determine whether the occurrence of TD is associated with CYP2D6 genotype in a cohort of Korean schizophrenics by employing a CYP450 GeneChip® oligonucleotide microarray and PCR assays to screen for 19 CYP2D6 alleles. Our results revealed that males with at least one decreased or loss of function allele have a moderately greater chance of developing TD than males with only wild-type alleles. Female schizophrenics did not have a significantly greater chance of developing TD. Our results demonstrate the utility of CYP2D6 microarrays to assess genotype status in this Korean cohort.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Glazer WM, Morgenstern H, Doucette JT . Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications J Clin Psychiatry 1993 54: (4) 133–139

    CAS  PubMed  Google Scholar 

  2. Casey DE . Tardive dyskinesia and atypical antipsychotic drugs Schizophr Res 1999 35: (Suppl) S61–S66

    Article  Google Scholar 

  3. Wszola BA, Newell KM, Sprague RL . Risk factors for tardive dyskinesia in a large population of youths and adults Exp Clin Psychopharmacol 2001 9: (3) 285–296

    Article  CAS  Google Scholar 

  4. Morgenstern H, Glazer WM . Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study Arch Gen Psychiatry 1993 50: (9) 723–733

    Article  CAS  Google Scholar 

  5. Morgenstern H, Glazer WM, Gibowski LD, Holmberg S . Predictors of tardive dyskinesia: results of a cross-sectional study in an outpatient population J Chronic Dis 1987 40: (4) 319–327

    Article  CAS  Google Scholar 

  6. Otani K, Aoshima T . Pharmacogenetics of classical and new antipsychotic drugs Ther Drug Monit 2000 22: (1) 118–121

    Article  CAS  Google Scholar 

  7. Marez D, Legrand M, Sabbagh N, Guidice JM, Spire C, Lafitte JJ et al . Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution Pharmacogenetics 1997 7: (3) 193–202

    Article  CAS  Google Scholar 

  8. Meyer UA, Zanger UM . Molecular mechanisms of genetic polymorphisms of drug metabolism Annu Rev Pharmacol Toxicol 1997 37: 269–296

    Article  CAS  Google Scholar 

  9. Wang SL, Huang JD, Lai MD, Liu BH, Lai ML . Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6 Clin Pharmacol Ther 1993 53: (4) 410–418

    Article  CAS  Google Scholar 

  10. Johansson I, Yue QY, Dahl ML, Heim M, Sawe J, Bertilsson L et al . Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine Eur J Clin Pharmacol 1991 40: (6) 553–556

    CAS  PubMed  Google Scholar 

  11. Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM et al . Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine and S-mephenytoin Clin Pharmacol Ther 1992 51: (4) 388–397

    Article  CAS  Google Scholar 

  12. Brockmoller J, Kirchheiner J, Meisel C, Roots I . Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment Pharmacogenomics 2000 1: (2) 125–151

    Article  CAS  Google Scholar 

  13. Kapitany T, Meszaros K, Lenzinger E, Schindler SD, Barnas C, Fuchs K et al . Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia Schizophr Res 1998 32: (2) 101–106

    Article  CAS  Google Scholar 

  14. Andreassen OA, MacEwan T, Gulbrandsen AK, McCreadie RG, Steen VM . Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients Psychopharmacology (Berl) 1997 131: (2) 174–179

    Article  CAS  Google Scholar 

  15. Ellingrod VL, Schultz SK, Arndt S . Association between cytochrome P4502D6 (CYP2D6) genotype, antipsychotic exposure, and abnormal involuntary movement scale (AIMS) score Psychiatr Genet 2000 10: (1) 9–11

    Article  CAS  Google Scholar 

  16. Armstrong M, Daly AK, Blennerhassett R, Ferrier N, Idle JR . Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype Br J Psychiatry 1997 170: 23–26

    Article  CAS  Google Scholar 

  17. Arthur H, Dahl ML, Siwers B, Sjoqvist F . Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia J Clin Psychopharmacol 1995 15: (3) 211–216

    Article  CAS  Google Scholar 

  18. Dahl ML, Yue QY, Roh HK, Johansson I, Sawe J, Sjoqvist F et al . Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects Pharmacogenetics 1995 5: (3) 159–164

    Article  CAS  Google Scholar 

  19. Roh HK, Dahl ML, Johansson I, Ingelman-Sundberg M, Cha YN, Bertilsson L . Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population Pharmacogenetics 1996 6: (5) 441–447

    Article  CAS  Google Scholar 

  20. Potkin SG, Shen Y, Pardes H, Phelps BH, Zhou D, Shu L et al . Haloperidol concentrations elevated in Chinese patients Psychiatry Res 1984 12: (2) 167–172

    Article  CAS  Google Scholar 

  21. Someya T, Suzuki Y, Shimoda K, Hirokane G, Morita S, Yokono A et al . The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: a preliminary study in a psychiatric population Psychiatry Clin Neurosci 1999 53: (5) 593–597

    Article  CAS  Google Scholar 

  22. Roh HK, Chung JY, Oh DY, Park CS, Svensson JO, Dahl ML et al . Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients Br J Clin Pharmacol 2001 52: (3) 265–271

    Article  CAS  Google Scholar 

  23. Suzuki Y, Someya T, Shimoda K, Hirokane G, Morita S, Yokono A et al . Importance of the cytochrome P450 2D6 genotype for the drug metabolic interaction between chlorpromazine and haloperidol Ther Drug Monit 2001 23: (4) 363–368

    Article  CAS  Google Scholar 

  24. Llerena A, Dahl ML, Ekqvist B, Bertilsson L . Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers Ther Drug Monit 1992 14: (3) 261–264

    Article  CAS  Google Scholar 

  25. Ohmori O, Suzuki T, Kojima H, Shinkai T, Terao T, Mita T et al . Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics Schizophr Res 1998 32: (2) 107–113

    Article  CAS  Google Scholar 

  26. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjoqvist F, Ingelman-Sundberg M . Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation Mol Pharmacol 1994 46: (3) 452–459

    CAS  PubMed  Google Scholar 

  27. Lam LC, Garcia-Barcelo MM, Ungvari GS, Tang WK, Lam VK, Kwong SL et al . Cytochrome P450 2D6 genotyping and association with tardive dyskinesia in Chinese schizophrenic patients Pharmacopsychiatry 2001 34: (6) 238–241

    Article  CAS  Google Scholar 

  28. Rey MJ, Schulz P, Costa C, Dick P, Tissot R . Guidelines for the dosage of neuroleptics. I: Chlorpromazine equivalents of orally administered neuroleptics Int Clin Psychopharmacol 1989 4: (2) 95–104

    Article  CAS  Google Scholar 

  29. Guy W . Assessment Manual for Psychopharmacology Publication ADM, U.S. Department of Health, Education and Welfare 1976

    Google Scholar 

  30. Schooler NR, Kane JM . Research diagnoses for tardive dyskinesia Arch Gen Psychiatry 1982 39: (4) 486–487

    CAS  PubMed  Google Scholar 

  31. Wang SL, Lai MD, Huang JD . G169R mutation diminishes the metabolic activity of CYP2D6 in Chinese Drug Metab Dispos 1999 27: (3) 385–388

    CAS  PubMed  Google Scholar 

  32. Yokoi T, Kosaka Y, Chida M, Chiba K, Nakamura H, Ishizaki T et al . A new CYP2D6 allele with a nine base insertion in exon 9 in a Japanese population associated with poor metabolizer phenotype Pharmacogenetics 1996 6: (5) 395–401

    Article  CAS  Google Scholar 

  33. Steen VM, Andreassen OA, Daly AK, Tefre T, Borresen AL, Idle JR et al . Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology Pharmacogenetics 1995 5: (4) 215–223

    Article  CAS  Google Scholar 

  34. Raimundo S, Fischer J, Eichelbaum M, Griese EU, Schwab M, Zanger UM . Elucidation of the genetic basis of the common ‘intermediate metabolizer’ phenotype for drug oxidation by CYP2D6 Pharmacogenetics 2000 10: (7) 577–581

    Article  CAS  Google Scholar 

  35. Claassen JD, Pascoe N, Schatzberg AF, Murphy Jr GM . Rapid detection of the C-1496G polymorphism in the CYP2D6*2 allele Clin Chem 2001 47: (12) 2153–2155

    CAS  PubMed  Google Scholar 

  36. Murphy Jr GM, Pollock BG, Kirshner MA, Pascoe N, Cheuk W, Mulsant BH et al . CYP2D6 genotyping with oligonucleotide microarrays and nortriptyline concentrations in geriatric depression Neuropsychopharmacology 2001 25: (5) 737–743

    Article  CAS  Google Scholar 

  37. Gaedigk A, Gotschall RR, Forbes NS, Simon SD, Kearns GL, Leeder JS . Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data Pharmacogenetics 1999 9: (6) 669–682

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We gratefully acknowledge Tom Ryder for advice in designing the new CYP450 GeneChip® microarray. This study was supported in part by a grant-in-aid from Research Foundation of Inje University (1999).

Author information

Authors and Affiliations

  1. Pharmacogenetics Department, Roche Molecular Systems, Alameda, CA, USA

    D Nikoloff, M Fairchild, N Patten, B A Fijal & W H Koch

  2. Department of Psychiatry, Inje University, Pusan Paik Hospital and Institute of Neuroscience, Pusan, Korea

    J-C Shim

  3. Division of Clinical Pharmacology, Department of Medicine and Pharmacology, Georgetown University, Georgetown University Medical Center, Washington, DC, USA

    A MacPherson

  4. Department of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, IN, USA

    D Flockhart

  5. Department of Pharmacology, Inje University College of Medicine and Clinical Pharmacology Center, Pusan, Korea

    Y-R Yoon & J-G Shin

  6. Department of Psychiatry, Chonnam National University Medical School, Pusan and Kwangju, Korea

    J-S Yoon & Y-H Kim

Authors
  1. D Nikoloff
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J-C Shim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Fairchild
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N Patten
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B A Fijal
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. W H Koch
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A MacPherson
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D Flockhart
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Y-R Yoon
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J-S Yoon
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Y-H Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. J-G Shin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J-G Shin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nikoloff, D., Shim, JC., Fairchild, M. et al. Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics. Pharmacogenomics J 2, 400–407 (2002). https://doi.org/10.1038/sj.tpj.6500138

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.tpj.6500138

Keywords

This article is cited by

Search

Advanced search

Quick links